FIBER OPTIC FLUORESCENCE DETECTOR FOR PHOTOSENSITIZER

Information

  • Research Project
  • 6513401
  • ApplicationId
    6513401
  • Core Project Number
    R44CA076913
  • Full Project Number
    5R44CA076913-03
  • Serial Number
    76913
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1998 - 26 years ago
  • Project End Date
    9/30/2004 - 20 years ago
  • Program Officer Name
    WONG, ROSEMARY S.
  • Budget Start Date
    4/1/2002 - 22 years ago
  • Budget End Date
    9/30/2004 - 20 years ago
  • Fiscal Year
    2002
  • Support Year
    3
  • Suffix
  • Award Notice Date
    4/22/2002 - 22 years ago
Organizations

FIBER OPTIC FLUORESCENCE DETECTOR FOR PHOTOSENSITIZER

DESCRIPTION: The efficacy and safety of photodynamic therapy (PDT) depends on an understanding of photosensitizer and light biology and dosimetry. Therefore, the ability to accurately determine photosensitizer levels in tumors and at-risk normal tissues is of utmost importance. The goal of this work is to develop and test a prototype system for fluorescence based measurement of photosensitizer uptake in tissue, to improve photodynamic therapy (PDT) dosimetry. The fiber optic system is designed to quantify photosensitizer concentration by detecting a fluorescence intensity signal which minimizes the impact of the tissue optical properties. The bundle is also designed to maximize the signal intensity, allowing quantitation of low concentrations of photosensitizers. Specialized designs have been developed for tissue surface measurement, interstitial measurement and sampling of drawn blood samples. The system is flexible enough to measure either porphyrin-based or phthalocyanine-based photosensitizers, and will specifically be tested in aminolevulinic acid-induced protoporphyrin IX (ALA - PpIX), Photofrin and aluminum disuiphonated phthalocynanine. The system design will be tested in three specific applications where PDT can be successfully commercialized, including (i) veterinary animal tumor therapy, (ii) research in experimental animal tumors, and (iii) adjuvant therapy for human brain tumors after resection. In order to successfully evaluate the system in these different PDT markets, prototype systems will be developed and tested in academic research labs at Dartmouth Medical School and the University of Toronto. The tests will (i) determine how robust the design is, (ii) determine if this dosimetry method improves PDT treatment outcome and (iii) demonstrate safety in human use, prior to commercial development. PROPOSED COMMERCIAL APPLICATION: Not Available

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    348814
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:348814\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    AURORA OPTICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    HANOVER
  • Organization State
    NH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    03755
  • Organization District
    UNITED STATES